Delivery Order SPE2DB22D1202-SPE2DB24FVEH5

Award Date 6/20/24
Potential Completion Date 6/21/24
Potential Value $12K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $1,753.24, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a vaccine product, to support federal healthcare programs. The award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November...
This federal contract award, valued at $13,784.70, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award covers the delivery of GARDASIL 9 SYRINGE 0.5ML, a vaccine product, with a completion date of December 16, 2024. The contract is structured as a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999...
This federal contract award, valued at $10,519.68, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a vaccine product, and has an ultimate completion date of January 15, 2025. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at...
This federal contract award, valued at $18,972.31, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a vaccine product. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves...
This federal contract award, valued at $6,836.17, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a vaccine product, with a performance period extending until January 16, 2025. This contract award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at...
This federal contract award, valued at $8,480.96, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a vaccine product, with a completion date of November 18, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued...
This federal contract award, valued at $30,983.23, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a vaccine product, to support federal healthcare programs. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical division. This IDC serves...
This federal contract award, valued at $4,298.84, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a vaccine product, to support military healthcare programs. The contract is structured as a Delivery Order under an Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support...
This federal contract award, valued at $35,018.20, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GARDASIL 9 syringes, a vaccine product, with a completion date of January 23, 2024. This award is a delivery order under a broader Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,474.74, is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a vaccine product. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves as a...
  • SPE2DB22D1202
    Indefinite Delivery Contract
  • SPE2DB22D1202-SPE2DB24FVEH5
    Delivery Order

This federal contract award of $11,782.50 was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a vaccination product, to support military healthcare programs.

The award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to the U.S. military and federal medical institutions globally. The contract does not have a set-aside designation, indicating open competition.

Generated 5/17/25, 9:54 AM